Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Esther Kissling; Mariette Hooiveld; Virginia Sandonis Martín; Iván Martínez-Baz; Naoma William; Ana-Maria Vilcu; Clara Mazagatos; Lisa Domegan; Simon de Lusignan; Adam Meijer; Ausenda Machado; Mia Brytting; Itziar Casado; Josephine-L K. Murray; Sylvie Belhillil; Amparo Larrauri; Joan O’Donnell; Ruby Tsang; Marit de Lange; Ana Paula Rodrigues; Maximilian Riess; Jesús Castilla; Mark Hamilton; Alessandra Falchi; Francisco Pozo; Linda Dunford; Jade Cogdale; Tessa Jansen; Raquel Guiomar; Theresa Enkirch; Cristina Burgui; Debbie Sigerson; Thierry Blanchon; Eva María Martínez Ochoa; Jeff Connell; Joanna Ellis; Rianne van Gageldonk-Lafeber; Irina Kislaya; Angela MC Rose; Marta Valenciano; I-MOVE-COVID-19 primary care study team

doi:10.2807/1560-7917.ES.2021.26.29.2100670

Rapid communication Open Access

Like 0

Download

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021
Esther Kissling¹ , Mariette Hooiveld² , Virginia Sandonis Martín³ , Iván Martínez-Baz^4,5 , Naoma William⁶ , Ana-Maria Vilcu⁷ , Clara Mazagatos^5,8 , Lisa Domegan⁹ , Simon de Lusignan^10,11 , Adam Meijer¹² , Ausenda Machado¹³ , Mia Brytting¹⁴ , Itziar Casado^4,5 , Josephine-L K. Murray⁶ , Sylvie Belhillil^15,16 , Amparo Larrauri^5,8 , Joan O’Donnell⁹ , Ruby Tsang^10,11 , Marit de Lange¹² , Ana Paula Rodrigues¹³ , Maximilian Riess¹⁴ , Jesús Castilla^4,5 , Mark Hamilton⁶ , Alessandra Falchi¹⁷ , Francisco Pozo³ , Linda Dunford¹⁸ , Jade Cogdale¹⁹ , Tessa Jansen² , Raquel Guiomar¹³ , Theresa Enkirch¹⁴ , Cristina Burgui^4,5 , Debbie Sigerson⁶ , Thierry Blanchon⁷ , Eva María Martínez Ochoa²⁰ , Jeff Connell¹⁸ , Joanna Ellis¹⁹ , Rianne van Gageldonk-Lafeber¹² , Irina Kislaya¹³ , Angela MC Rose¹ , Marta Valenciano¹ , I-MOVE-COVID-19 primary care study team²¹
View Affiliations Hide Affiliations

Affiliations: ¹ Epiconcept, Paris, France ² Nivel, Utrecht, the Netherlands ³ National Centre for Microbiology, Institute of Health Carlos III, Madrid, Spain ⁴ Instituto de Salud Pública de Navarra (IdiSNA), Pamplona, Spain ⁵ Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Institute of Health Carlos III, Madrid, Spain ⁶ Public Health Scotland, Glasgow, Scotland ⁷ INSERM, Sorbonne Université, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France ⁸ National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain ⁹ Health Service Executive-Health Protection Surveillance Centre, Dublin, Ireland ¹⁰ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK ¹¹ Royal College of General Practitioners Research and Surveillance Centre, London, UK ¹² National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands ¹³ Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal ¹⁴ The Public Health Agency of Sweden, Stockholm, Sweden ¹⁵ Unité de Génétique Moléculaire des Virus à ARN, UMR 3569 CNRS, Université Paris Diderot SPC, Institut Pasteur, Paris, France ¹⁶ CNR des virus des infections respiratoires, Institut Pasteur, Paris, France ¹⁷ Laboratoire de Virologie, Université de Corse-Inserm, Corte, France ¹⁸ National Virus Reference Laboratory, University College Dublin, Dublin, Ireland ¹⁹ Public Health England, London, England ²⁰ Servicio de Epidemiología y Prevención Sanitaria, Dirección General de Salud Pública, Consumo y Cuidados, La Rioja, Spain ²¹ The members of the I-MOVE-COVID-19 primary care study team are listed in the Investigators tab

Correspondence:
Esther Kissling
e.kissling epiconcept.fr
View Collaborators

I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva.

View Citation Hide Citation

Citation style for this article: Kissling Esther, Hooiveld Mariette, Sandonis Martín Virginia, Martínez-Baz Iván, William Naoma, Vilcu Ana-Maria, Mazagatos Clara, Domegan Lisa, de Lusignan Simon, Meijer Adam, Machado Ausenda, Brytting Mia, Casado Itziar, Murray Josephine-L K., Belhillil Sylvie, Larrauri Amparo, O’Donnell Joan, Tsang Ruby, de Lange Marit, Rodrigues Ana Paula, Riess Maximilian, Castilla Jesús, Hamilton Mark, Falchi Alessandra, Pozo Francisco, Dunford Linda, Cogdale Jade, Jansen Tessa, Guiomar Raquel, Enkirch Theresa, Burgui Cristina, Sigerson Debbie, Blanchon Thierry, Martínez Ochoa Eva María, Connell Jeff, Ellis Joanna, van Gageldonk-Lafeber Rianne, Kislaya Irina, Rose Angela MC, Valenciano Marta, I-MOVE-COVID-19 primary care study team. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Euro Surveill. 2021;26(29):pii=2100670. https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670 Received: 05 Jul 2021; Accepted: 22 Jul 2021

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45–74) for one dose only and 89% (95% CI: 79–94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

This work is licensed under a Creative Commons Attribution 4.0 International License.

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.29.2100670

2021-07-22

2024-12-22

Click here for cited by

/content/10.2807/1560-7917.ES.2021.26.29.2100670

Full text loading...

/deliver/fulltext/eurosurveillance/26/29/eurosurv-26-29_4.html?itemId=/content/10.2807/1560-7917.ES.2021.26.29.2100670&mimeType=html&fmt=ahah

References

Influenza - Monitoring Vaccine Effectiveness in Europe (I-MOVE). I-MOVE-COVID-19 European primary care and hospital networks. I-MOVE. [Accessed: 22 Jun 2021]. Available from: https://www.imoveflu.org/i-move-covid-19/
Epiconcept. COVID-19 vaccine effectiveness at primary care level in Europe: I-MOVE-COVID-19 generic protocol. Paris: Epiconcept. [Accessed: 22 Jun 2021]. Available from: https://www.imoveflu.org/wp-content/uploads/2021/05/I-MOVE-COVID-19-primary-care-COVID-19-vaccine-effectiveness-protocol-v2.3.pdf
Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8. https://doi.org/10.1016/j.vaccine.2013.02.053 PMID: 23499601
Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373(1088):n1088. https://doi.org/10.1136/bmj.n1088 PMID: 33985964
Chodick G, Tene L, Patalon T, Gazit S, Ben Tov A, Cohen D, et al. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Netw Open. 2021;4(6):e2115985. https://doi.org/10.1001/jamanetworkopen.2021.15985 PMID: 34097044
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412-23. https://doi.org/10.1056/NEJMoa2101765 PMID: 33626250
Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29. https://doi.org/10.1016/S0140-6736(21)00947-8 PMID: 33964222
Martínez-Baz I, Miqueleiz A, Casado I, Navascués A, Trobajo-Sanmartín C, Burgui C, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Euro Surveill. 2021;26(21). https://doi.org/10.2807/1560-7917.ES.2021.26.21.2100438 PMID: 34047271
Hernández AF, Calina D, Poulas K, Docea AO, Tsatsakis AM. Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicol Rep. 2021;8:871-9. https://doi.org/10.1016/j.toxrep.2021.04.003 PMID: 33898273
European Centre for Disease Prevention and Control (ECDC). COVID-19 vaccine rollout overview. Stockholm: ECDC. 2021. Available from: https://covid19-vaccine-report.ecdc.europa.eu/#3_Uptake_of_at_least_one_vaccine_dose_among_adults
Greenwood M, Yule GU. The Statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. Proc R Soc Med. 1915;8(Sect Epidemiol State Med):113-94. PMID: 19978918
Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;24:35(36):4796-800. https://doi.org/10.1016/j.vaccine.2017.07.003
Patel MM, Jackson ML, Ferdinands J. Postlicensure Evaluation of COVID-19 Vaccines. JAMA. 2020;324(19):1939-40. https://doi.org/10.1001/jama.2020.19328 PMID: 33064144
Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. Vaccine. 2021 Jun;S0264410X21007076. https://doi.org/10.1016/j.vaccine.2021.05.099

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Citation style for this article: <a href="/search?value1=Esther+Kissling&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kissling Esther</a>, <a href="/search?value1=Mariette+Hooiveld&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hooiveld Mariette</a>, <a href="/search?value1=Virginia+Sandonis+Mart%C3%ADn&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sandonis Martín Virginia</a>, <a href="/search?value1=Iv%C3%A1n+Mart%C3%ADnez-Baz&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez-Baz Iván</a>, <a href="/search?value1=Naoma+William&option1=author&noRedirect=true" class="nonDisambigAuthorLink">William Naoma</a>, <a href="/search?value1=Ana-Maria+Vilcu&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vilcu Ana-Maria</a>, <a href="/search?value1=Clara+Mazagatos&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mazagatos Clara</a>, <a href="/search?value1=Lisa+Domegan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Domegan Lisa</a>, <a href="/search?value1=Simon+de+Lusignan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Lusignan Simon</a>, <a href="/search?value1=Adam+Meijer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Meijer Adam</a>, <a href="/search?value1=Ausenda+Machado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Machado Ausenda</a>, <a href="/search?value1=Mia+Brytting&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Brytting Mia</a>, <a href="/search?value1=Itziar+Casado&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Casado Itziar</a>, <a href="/search?value1=Josephine-L+K.+Murray&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Murray Josephine-L K.</a>, <a href="/search?value1=Sylvie+Belhillil&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Belhillil Sylvie</a>, <a href="/search?value1=Amparo+Larrauri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Larrauri Amparo</a>, <a href="/search?value1=Joan+O%E2%80%99Donnell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">O’Donnell Joan</a>, <a href="/search?value1=Ruby+Tsang&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Tsang Ruby</a>, <a href="/search?value1=Marit+de+Lange&option1=author&noRedirect=true" class="nonDisambigAuthorLink">de Lange Marit</a>, <a href="/search?value1=Ana+Paula+Rodrigues&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rodrigues Ana Paula</a>, <a href="/search?value1=Maximilian+Riess&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Riess Maximilian</a>, <a href="/search?value1=Jes%C3%BAs+Castilla&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Castilla Jesús</a>, <a href="/search?value1=Mark+Hamilton&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hamilton Mark</a>, <a href="/search?value1=Alessandra+Falchi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Falchi Alessandra</a>, <a href="/search?value1=Francisco+Pozo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Pozo Francisco</a>, <a href="/search?value1=Linda+Dunford&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Dunford Linda</a>, <a href="/search?value1=Jade+Cogdale&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cogdale Jade</a>, <a href="/search?value1=Tessa+Jansen&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jansen Tessa</a>, <a href="/search?value1=Raquel+Guiomar&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Guiomar Raquel</a>, <a href="/search?value1=Theresa+Enkirch&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Enkirch Theresa</a>, <a href="/search?value1=Cristina+Burgui&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Burgui Cristina</a>, <a href="/search?value1=Debbie+Sigerson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sigerson Debbie</a>, <a href="/search?value1=Thierry+Blanchon&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Blanchon Thierry</a>, <a href="/search?value1=Eva+Mar%C3%ADa+Mart%C3%ADnez+Ochoa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Martínez Ochoa Eva María</a>, <a href="/search?value1=Jeff+Connell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Connell Jeff</a>, <a href="/search?value1=Joanna+Ellis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ellis Joanna</a>, <a href="/search?value1=Rianne+van+Gageldonk-Lafeber&option1=author&noRedirect=true" class="nonDisambigAuthorLink">van Gageldonk-Lafeber Rianne</a>, <a href="/search?value1=Irina+Kislaya&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kislaya Irina</a>, <a href="/search?value1=Angela+MC+Rose&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rose Angela MC</a>, <a href="/search?value1=Marta+Valenciano&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Valenciano Marta</a>, <a href="/search?value1=I-MOVE-COVID-19+primary+care+study+team&option1=author&noRedirect=true" class="nonDisambigAuthorLink">I-MOVE-COVID-19 primary care study team</a>. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(29):pii=2100670. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100670</a> Received: 05 Jul 2021;   Accepted: 22 Jul 2021

/content/10.2807/1560-7917.ES.2021.26.29.2100670

Data & Media loading...

Supplementary data

Download
- Supplementary Material

Submit comment

Comment moderation successfully completed

Submit your article here

Submit an Article

Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Abstract

Click here for cited by

Supplementary data

Supplementary Material